Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Annovis Bio Inc (NY: ANVS )

7.070 +0.420 (+6.32%)
Official Closing Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio Inc

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
ANNOVIS BIO SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Annovis Bio, Inc. - ANVS
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER ALERT: PHG ANVS ATIP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / August 19, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a... 
From The Law Offices of Vincent Wong
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SRAC, ATHA and ANVS
NEW YORK, NY / ACCESSWIRE / August 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to... 
From The Klein Law Firm
Via AccessWire
Topics Fraud Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
CLASS ACTION UPDATE for RKT, BZ and ANVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
Exposures Financial Legal
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
From Glancy Prongay & Murray LLP
Via Business Wire
ANNOVIS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ANVS ALERT: Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ANVS
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ANVS CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Annovis Bio, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
ANNOVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Annovis Bio, Inc. on Behalf of Annovis Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
61 Biggest Movers From Yesterday
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.... 
Via Benzinga
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Annovis Bio, Inc.
From Kirby McInerney LLP
Via Business Wire
40 Stocks Moving In Monday's Mid-Day Session
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:... 
Via Benzinga
Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business. 
Via The Motley Fool
63 Biggest Movers From Friday
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the... 
Via Benzinga
Exposures Product Safety
ANVS Stock: The Alzheimer’s Drug News That Has Annovis Bio Plunging Today
Shares of ANVS stock are plummeting on Thursday after Annovis Bio reported weak results from two clinical trials for its leading drug. 
Via InvestorPlace
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
70 Biggest Movers From Yesterday
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private... 
Via Benzinga
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases... 
Via Benzinga
Mid-Day Market Update: LendingClub Surges Following Strong Q2 Results; Atreca Shares Plummet
Midway through trading Thursday, the Dow traded up 0.55% to 35,122.75 while the NASDAQ rose 0.47% to 14,831.28. The S&P also rose, gaining 0.61% to 4,427.36. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
44 Stocks Moving In Thursday's Mid-Day Session
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 47.6% to $2.8198 after the company announced it received registration approval for UroShield from TGA Australia.... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Mastercard Profit Beats Estimates
Following the market opening Thursday, the Dow traded up 0.44% to 35,085.92 while the NASDAQ rose 0.27% to 14,802.51. The S&P also rose, gaining 0.45% to 4,420.49. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.